NCT02113982 - Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

138

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 1, 2020

Study Completion Date

March 12, 2020

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Acute Myeloid Leukemia (AML)

Interventions

DRUG

Tagraxofusp

Trial Locations (9)

Columbia University Medical Center, New York

H. Lee Moffiitt Cancer Center & Research Institute, Tampa

Roswell Park Cancer Institute, Buffalo

University of Pittsburgh Medical Center Presbyterian Shady Side, Pittsburgh

Duke University Medical Center, Durham

Ohio State University, Columbus

MD Anderson Cancer Center, Houston

City of Hope National Medical Center, Duarte

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Stemline Therapeutics, Inc.

INDUSTRY